Regeneron Pharmaceuticals, Inc is a biotechnology company founded in 1988 and headquartered in the United States. The company invents, develops, and commercializes medicines for people with serious diseases, operating across a global network with a team of over 15,000 employees. Founded and led by physician-scientists, Regeneron maintains a focus on translating scientific research into therapies.
The company's technical capabilities span antibody discovery, genetic medicine, and data-powered insights. Its proprietary VelociSuite® technologies enable the discovery of optimized fully human antibodies and new classes of bispecific antibodies. The Regeneron Genetics Center® (RGC) provides data-driven insights to advance the next frontier of medicine.
Regeneron has been in operation for over 35 years and employs more than 1,400 team members holding MDs and/or PhDs. The company operates in the biotechnology and pharmaceuticals industry verticals.
